166-POS

Abstract

Objectives To determine if urine MMP levels were increased in women with PE. Urine levels of kidney injury biomarkers neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) were also determined. Methods Urine specimen were collected from 86 pregnant women (28 normotensive, 15 complicated with chronic hypertension, 11 mild PE, and 32 severe PE) at the time of recruitment before delivery and 6–8 weeks postpartum. Urine concentrations of MMP2, MMP9, metallopeptidase inhibitor 2 (TIMP2), NGAL, and KIM-1 were measured by ELISA. All samples were assayed in duplicate. Urine creatinine concentration was also determined. Data are expressed as mean ± SE ng/mg creatinine and analyzed by ANOVA with Newman–Keuls as the post hoc test. A probability level less than 0.05 was considered statistically different. Results Urine concentrations of MMP2, MMP9, NGAL, and KIM-1 were significantly higher in women with severe PE than in normotensive pregnancies, MMP2: 3.033±0.612 vs. 1.411 ± 0.219 ng/mg creatinine, p p p p Conclusions NGAL and KIM-1 are biomarkers used to evaluate risk of renal damage in kidney diseases. Podocyte shedding is significantly increased in severe PE. The findings of increased urine levels of MMP2 and MMP9 associated with increased NGAL and KIM-1 in women with severe PE suggest that increased renal matrix metallopeptidase production may contribute to the glomerular barrier injury and podocyte shedding in PE. NGAL and KIM-1 could also be used as biomarkers to evaluate kidney dysfunction in PE. Disclosures Y. Wang: None. Y. Gu: None. S. Loyd: None. L.J. Groome: None.